Upadacitinib in Active Ankylosing Spondylitis: 1-Year Results From the Double-Blind, Placebo-Controlled SELECT-AXIS 1 Study and Open-Label Extension

Analysis of 178 patients completing week 14 on study drug and entering the open-label extension found upadacitinib was associated with sustained efficacy over 1 year in adults with active ankylosing spondylitis, with a similar efficacy noted in those crossing over from placebo.

Source:

Arthritis & Rheumatology